Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01212406
Other study ID # VIT001
Secondary ID
Status Completed
Phase Phase 4
First received September 28, 2010
Last updated November 10, 2015
Start date October 2010
Est. completion date August 2015

Study information

Verified date October 2013
Source Universitaire Ziekenhuizen Leuven
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health ProductsBelgium: Ethics Committee
Study type Interventional

Clinical Trial Summary

Vitamin D deficiency occurs in around 50% of our transplant population. Preventive treatment with Vitamin D (D-cure) can reduce the prevalence of Bronchiolitis Obliterans Syndrome after lung transplantation


Description:

- Prospective, interventional, randomized, double-blind, placebo-controlled trial.

- Clinical setting (tertiary University Hospital).

- Investigator-driven, no pharmaceutical sponsor.

- Lung transplant recipients.

- Add-on of study-drug (placebo or vitamin D) to 'standard of care' (standardized, routine immunosuppressive and infectious prophylactic protocol).

- 1:1 inclusion ratio (placebo:Vitamin D).

- Randomisation at discharge after informed consent.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date August 2015
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Stable LTx recipients at discharge after transplantation.

- Signed informed consent

- Adult (age at least 18 years old at moment of transplantation)

- Able to take oral medication

Exclusion Criteria:

- Prolonged and/or complicated Intensive care unit-course after transplantation.

- Early (<30 days post-transplant) post-operative death

- Major suture problems (airway stenosis or stent)

- Retransplantation (lung)

- Previous transplantation (solid organ)

- Multi-organ transplantation (lung+ other solid organ)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Drug:
Vitamin D
Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years

Locations

Country Name City State
Belgium UZ Gasthuisberg Leuven

Sponsors (2)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven Katholieke Universiteit Leuven

Country where clinical trial is conducted

Belgium, 

References & Publications (5)

Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002 Mar;21(3):297-310. Review. — View Citation

Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax. 2010 Mar;65(3):215-20. doi: 10.1136/thx.2009.120659. Epub 2009 Dec 8. — View Citation

Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zügel U, Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):142-50. doi: 10.1016/j.jsbmb.2009.11.004. Epub 2009 Nov 17. — View Citation

Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008 Oct;32(4):832-43. doi: 10.1183/09031936.00134307. Review. — View Citation

Zittermann A, Schleithoff SS, Götting C, Fuchs U, Kuhn J, Kleesiek K, Tenderich G, Koerfer R. Calcitriol deficiency and 1-year mortality in cardiac transplant recipients. Transplantation. 2009 Jan 15;87(1):118-24. doi: 10.1097/TP.0b013e31818c2708. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of Bronchiolitis Obliterans syndrome (BOS) (grade 1) at 2 years after transplantation BOS= decline in forced expiratory volume in 1 second (FEV1) with at least 80% compared to the best post-operative value 2 years after transplantation No
Primary Prevalence of BOS (grade 1) at 3 years after transplantation her-evaluation of data 3 years after transplantation No
Secondary Bronchoalveolar lavage cellularity, protein and mRNA concentration and microbiology during 2 and 3y of follow-up No
Secondary Peripheral blood Protein and mRNA concentration, cellularity During 2 and 3 years of follow-up No
Secondary Rejection rates Acute rejection and lymphocytic bronchiolitis rates During 2 and 3 years of follow-up No
Secondary Reflux clinical and biochemical approach During 2 and 3 years of follow-up No
Secondary Infection rates cytomegalovirus (CMV) and non- CMV infection rates During 2 and 3 years of follow-up No
See also
  Status Clinical Trial Phase
Completed NCT02581111 - Naloxone for Optimizing Hypoxemia Of Lung Donors Phase 2/Phase 3
Recruiting NCT02177916 - Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation N/A
Not yet recruiting NCT01394835 - Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients Phase 2
Not yet recruiting NCT01162148 - Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation N/A
Completed NCT01204970 - Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients N/A
Active, not recruiting NCT00980967 - Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study N/A
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Recruiting NCT00163696 - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease N/A
Completed NCT00177684 - Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Phase 3
Completed NCT00163891 - Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients N/A
Completed NCT03668483 - Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx N/A
Not yet recruiting NCT02855372 - Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT) N/A
Completed NCT01211509 - Montelukast in Bronchiolitis Obliterans Syndrome Phase 4
Not yet recruiting NCT00808600 - Empowerment of Lung and Heart-lung Transplant Patients N/A
Completed NCT00553397 - Live Lung Donor Retrospective Study N/A
Completed NCT00402805 - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Phase 4
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Terminated NCT00235651 - Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients Phase 3
Active, not recruiting NCT02936505 - Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD. N/A
Recruiting NCT03798860 - Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation